Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - arikayce
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp5567fe4258ad803585d82a002a45d53a
identifier: http://ema.europa.eu/identifier
/EU/1/20/1469/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: ARIKAYCE liposomal 590 mg nebuliser dispersion
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-5567fe4258ad803585d82a002a45d53a
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/20/1469/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - arikayce
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
ARIKAYCE liposomal is an antibiotic that contains the active ingredient amikacin. Amikacin belongs to a group of antibiotics called aminoglycosides which stop the growth of certain bacteria that cause infections.
ARIKAYCE liposomal is used by inhalation to treat lung infection caused by Mycobacterium avium Complex in adults with limited treatment options who do not have cystic fibrosis.
Do not use ARIKAYCE liposomal
Warnings and precautions Talk to your doctor or pharmacist before using ARIKAYCE liposomal if:
Talk to your doctor immediately if, whilst using ARIKAYCE liposomal you experience any of the below:
Other medicines and ARIKAYCE liposomal Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Special care is needed if you are taking other medicines, as some could interact with ARIKAYCE liposomal, for example:
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, the use of ARIKAYCE liposomal should be avoided. Ask your doctor or pharmacist for advice before using this medicine.
If you become pregnant while using ARIKAYCE liposomal, inform your doctor. He will advise whether to stop using ARIKAYCE liposomal.
It is not known if amikacin passes into breast milk in humans. If you are breastfeeding, your doctor will advise you whether to stop breast-feeding or stop treatment with this medicine.
Driving and using machines ARIKAYCE liposomal can cause dizziness and other vestibular disturbances, such as vertigo and balance disorders. You are advised not to drive or operate machinery while inhaling ARIKAYCE liposomal. If you have questions, please talk to your doctor.
Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
The recommended dose is one vial of ARIKAYCE liposomal inhaled in your mouth once a day, using the Lamira Nebuliser. After 6 months of treatment your doctor will advise whether to continue or to stop treatment. The maximum duration of treatment is 18 months.
Taking ARIKAYCE liposomal
If you use a bronchodilator ( reliever ), use that first, before using ARIKAYCE liposomal. Each vial is for single use only.
How and when do you replace the Lamira Nebuliser Handset? One Lamira Nebuliser Handset should be used for one 28-day treatment course. The aerosol head should be replaced weekly. There are 4 aerosol heads provided in each ARIKAYCE liposomal carton. Please refer to the manufacturer s instructions for use for cleaning and storage advice.
If you use more ARIKAYCE liposomal than you should Tell your doctor immediately if you are concerned that you may have used too much of this medicine.
If you forget to use ARIKAYCE liposomal If you forget to take your medicine, take it as soon as possible on the day of the missed dose. Do not take more than one dose on the same day to make up for a forgotten dose.
If you stop using ARIKAYCE liposomal You must tell your doctor if you decide to stop using ARIKAYCE liposomal for any reason.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor immediately if:
Other side effects: Tell your doctor or pharmacist if you experience any of the following:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effect (may affect up to 1 in 100 people)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vial after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator (2 C 8 C). Do not freeze, discard any vial that has been frozen.
If the dose you want to use is refrigerated, remove the vial from the refrigerator and allow it to come to room temperature before using it.
Alternatively, ARIKAYCE liposomal can be stored at room temperature below 25 C, but only for up to 4 weeks. Once at room temperature, any unused medicinal product must be discarded at the end of 4 weeks.
This medicine is a milky white liquid in a clear vial. Do not use if you notice change in colour or any small lumps floating in the vial.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What ARIKAYCE liposomal contains
What ARIKAYCE liposomal looks like and contents of the pack ARIKAYCE liposomal is a white to off-white, milky nebuliser dispersion in a 10 mL glass vial sealed with a rubber stopper and a metal seal with a flip tear-off cap.
The 28 vials are provided in a carton for a 28-day supply; one vial per day. One ARIKAYCE liposomal carton contains 4 inner cartons, each containing 7 vials and one aerosol head. The 28-day supply pack also contains 1 Lamira Nebuliser Handset.
Marketing Authorisation Holder Insmed Netherlands B.V. Stadsplateau 7 3521 AZ Utrecht Netherlands
Manufacturer Almac Pharma Services (Ireland) Ltd. Finnabair Industrial Estate,
Dundalk, Co. Louth, A91 P9KD, Ireland
This leaflet was last revised in {month/YYYY}.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-5567fe4258ad803585d82a002a45d53a
Resource Composition:
Generated Narrative: Composition composition-en-5567fe4258ad803585d82a002a45d53a
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1469/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - arikayce
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp5567fe4258ad803585d82a002a45d53a
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp5567fe4258ad803585d82a002a45d53a
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1469/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: ARIKAYCE liposomal 590 mg nebuliser dispersion
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en